U.S. market Closed. Opens in 9 hours 57 minutes

NXL | Nexalin Technology, Inc. Stock Overview

(Stock Exchange: NASDAQ)
Day's Range 2.6118 - 3.11
52 Week Range 0.2530 - 4.05
Beta N/A
Implied Volatility N/A
IV Rank N/A
Day's Volume 2,049,395
Average Volume 1,324,682
Shares Outstanding 10,586,562
Market Cap 28,689,583
Sector Healthcare
Industry Medical - Devices
IPO Date 2022-09-16
Valuation
Profitability
Growth
Health
P/E Ratio -3.76
Forward P/E Ratio N/A
EPS -0.72
1YR Price Target N/A
Dividend Yield N/A
Dividend Per Share N/A
Dividend ExDate N/A
Dividend PayDate N/A
Employees 6
Country USA
Website NXL
Nexalin Technology, Inc., a medical device company, designs and develops neurostimulation products for the treatment of mental health in the United States and China. It licenses and markets Nexalin Device, a non-invasive and drug-free therapy for the treatment of anxiety and insomnia. The company's Nexalin device emits a patented frequency-based waveform, which stimulates a positive response from the mid-brain structures associated with various mental health disorders. It also engages in the development of Generation 2, a medical device that is in clinical trials for the treatment of substance abuse issues related to opiates, chronic pain, Alzheimer's disease, and dementia. The company was incorporated in 2021 and is headquartered in Houston, Texas.
*Chart delayed
Analyzing fundamentals for NXL we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is unacceptably poor, Growth is desperately bad and Health is very weak. For more detailed analysis please see NXL Fundamentals page.

Watching at NXL technicals we can see that long-term trend is bullish, the same as bullish middle-term trend, as well as bullish short-term trend. More technicals details can be found on NXL Technicals page.
An error has occurred. This application may no longer respond until reloaded. Reload 🗙